Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPiroxicam is an anti-inflammatory; highly selective inhibitor of COX-1 (ratio of IC50 values for COX-2/COX-1 ~ 600).
M. Wt | 331.35 |
Formula | C15H13N3O4S |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 36322-90-4 |
PubChem ID | 54676228 |
InChI Key | QYSPLQLAKJAUJT-UHFFFAOYSA-N |
Smiles | CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CC=C2)S1(=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Mitchell et al (1995) Cyclooxygenase-2. Regulation and relevance in inflammation. Biochem.Pharmacol. 50 1535 PMID: 7503754
Merck Index 12 7661
Keywords: Piroxicam, Piroxicam supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, COX, Oxygenases, Oxidases, 0960, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Piroxicam.
There are currently no reviews for this product. Be the first to review Piroxicam and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.